| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $16.0M | +0.0% |
| SG&A Expense | $7.9M | +35.7% |
| Operating Income | -$18.1M | -21.5% |
| Income Tax | $0 | — |
| Net Income | -$16.8M | -16.2% |
| EPS (Basic) | -$0.30 | +97.1% |
| EPS (Diluted) | -$0.30 | +97.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $133.4M | +1258.2% |
| Current Assets | $134.2M | +1179.0% |
| Total Assets | $134.3M | +1134.8% |
| Current Liabilities | $4.6M | +43.3% |
| Total Liabilities | $5.0M | +46.5% |
| Stockholders' Equity | $129.4M | +1626.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$10.8M | +11.0% |
| Financing Cash Flow | $134.4M | +1303.0% |